Original Article
Anemia of Cancer in Intermediate‐Grade Non‐Hodgkin's Lymphoma
Abstract
Background. Current literature suggests that anemia at baseline is an important adverse prognostic factor for lymphoma‐related outcomes. We evaluated the prevalence, risk factors, and prognostic value of anemia in patients with intermediate‐grade non‐Hodgkin's lymphoma (IGNHL) treated in a community‐based practice.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
